Found 20 clinical trials
Medical Food for the Dietary Management of Metastatic Pancreatic Cancer
Subjects will be receiving two FDA approved first line drug therapies, gemcitabine and nab-paclitaxel (gem+nabP), that are routinely prescribed in combination for metastatic pancreatic cancer as part of their routine care.
- 0 views
- 15 Oct, 2021
Pyrotinib Trastuzumab Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
This study aims to evaluate the efficacy and safety of pyrotinib in combination with trastuzumab, pertuzumab and nab-paclitaxel as neoadjuvant therapy in early stage or locally advanced HER2-positive breast cancer.
- 0 views
- 16 Feb, 2024
- 1 location
Clinical Study of Nab-paclitaxel Combined With Toripalimab in Local Advanced or Metastatic G/GEJ Carcinoma
This study is to evaluate the efficacy and safety of Albumin-bound paclitaxel combined with Toripalimab as first-line/second-line treatment of local advanced or metastatic gastric or gastroesophageal junction carcinoma.
- 0 views
- 05 Aug, 2020
This is a Study to Evaluate the Safety and Tolerability of the Study Medication ABL001 in Combiation With Irinotecan/Paclitaxel and to Determine the Maximum Tolerated Dose and/or Recommended Phase 2 Study Dose of ABL001 in Combination With Irinotecan/Paclitaxel.
The purpose of this open-label, combination dose escalation, Phase 1b/2a clinical trial is to evaluate the safety, pharmacokinetics and anti-tumor activity and determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of combination therapy with ABL001(NOV1501) and Paclitaxel/Irinotecan .
- 0 views
- 05 Aug, 2020
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
Participants will repeat the screening tests during the study. Participants will receive nilotinib and paclitaxel. The drugs are given in 28-day cycles. Nilotinib is a capsule taken by mouth twice a day. Paclitaxel will be given intravenously by peripheral line or central line once a week for the first 3 …
- 0 views
- 16 Feb, 2024
- 1 location
Prospective Multicenter Non-randomized Single Arm Clinical Trial to Evaluate the Safety and Efficacy of e-PTFE Grafts Inner Surface-treated With Paclitaxel as an Access for Hemodialysis in Patients With End-stage Renal Disease.
This prospective, multicenter, non-randomized, single-arm Clinical trial aims to evaluate the safety and effectiveness of the use of paclitaxel-coated arteriovenous graft (AVG) on the inner wall of ePTFE graft, which is designed to reduce neointimal hyperplasia that causes stenosis and thrombosis after implantation of AVG.
- 0 views
- 16 Feb, 2024
- 1 location
Medical Food for the Dietary Management of Metastatic Pancreatic Cancer
Subjects will be receiving two FDA approved first line drug therapies, gemcitabine and nab-paclitaxel (gem+nabP), that are routinely prescribed in combination for metastatic pancreatic cancer as part of their routine care.
- 0 views
- 15 Oct, 2021
- 1 location
Medical Food for the Dietary Management of Metastatic Pancreatic Cancer
Subjects will be receiving two FDA approved first line drug therapies, gemcitabine and nab-paclitaxel (gem+nabP), that are routinely prescribed in combination for metastatic pancreatic cancer as part of their routine care.
- 0 views
- 15 Oct, 2021
Nivolumab Ipilimumab and Chemoradiation in Treating Patients With Locally Advanced Pancreatic Cancer.
To explore the safety and synergy of the proposed combinatorial approach, participants with locally advanced PC will receive nivolumab and ipilimumab administered in combination with gemcitabine and nab-paclitaxel followed by immune-chemoradiation.
- 0 views
- 16 Feb, 2024
- 1 location
PAXG Out in the Country
The objective of this study is to assess the reproducibility of PAXG regimen as first-line/primary chemotherapy in daily clinical practice in Pancreatic Ductal Adenocarcinoma (PDAC) borderline resectable, locally advanced or metastatic patients out of a large volume center.
- 0 views
- 05 Aug, 2020
- 1
- 2